|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
����ϩ |
|
Ƥ��,��Ӧ�� |
|
���� |
| ��������������� | |
|
�ӻ� |
|
���� |
| PubMed | |
|
Article by |
|
Article by |
����ϩ����Ӧ��Ƥ��
�ӻ�, ����
ɽ����ѧ��³ҽԺƤ����, ����250012
����ϩ�ǻ�����ϩ��ͨ��5-֬����ø;���Ĵ�л����,��һ����Ҫ��֬��ǰ��֢����,����Ӧ��Ƥ�ķ�������������Ҫ���á�Ŀǰ���������������ڼ����о��϶�,����ϩ���ڼ�������Ӧ��Ƥ���ѳ���Ӧ�����ٴ�ʵ����
[2] Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol, 1999, 103:125-138.
[3] Leung DY. Immunopathogenesis of Atopic Dermatitis. Immunol Allergy Clin North Am, 2002, 22:73-90.
[4] Taskapan MO. Zileuton and atopic dermatitis. Ann Allergy Asthma Immunol, 2001, 87:162-163.
[5] Bender B. Psychologic dysfunction associated with atopic dermatitis.Immunol Allergy Clin North Am,2002, 22:43-54.
[6] Leiferman KM. A role for eosinophils in atopic dermatitis. J Am Acad Dermatol,2001,45(1 Suppl):S21-S24.
[7] Bunikowski R, Mielke M, Skarabis H, et al. Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis. J Allergy Clin Immunol, 1999, 103:119-124.
[8] Pucci N, Lombardi E, Novembre E,et al. Urinary eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis:correlation with disease activity. J Allergy Clin Immunol, 2000, 105:353-357.
[9] Wuthrich B, Schmid-Grendelmeier P. The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated ("extrinsic") and the nonallergic ("intrinsic")AEDS. J Investig Allergol Clin Immunol, 2003,13:1-5.
[10] Eichenfield LF, Hanifin JM, Beck LA, et al. Atopic dermatitis and asthma:parallels in the evolution of treatment. Pediatrics, 2003,111:608-616.
[11] Iversen L, Kristensen P, Gron B, et al. Human epidermis transforms exogenous leukotriene A4 into peptide leukotrienes:possible role in transcellular metabolism. Arch Dermatol Res, 1994, 286:261-266.
[12] Kagi MK. Leukotriene receptor antagonists--a novel therapeutic approach in atopic dermatitis?Dermatology, 2001, 203:280-283.
[13] De Lepeleire I, Reiss TF, Rochette F, et al. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther, 1997, 61:83-92.
[14] Donnelly AL, Glass M, Minkwitz MC, et al. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med, 1995, 151:1734-1739.
[15] Dahlen SE. Leukotriene receptors. Clin Rev Allergy Immunol,1999,17:179-191.
[16] Sansom JE, Taylor GW, Dollery CT, et al. Urinary leukotriene F4levels in patients with atopic dermatitis. Br J Dermatol, 1997, 136:790-791.
[17] Adamek-Guzik T, Guzik TJ, Czerniawska-Mysik G,et al. Urinary leukotriene levels are increased during exacerbation of atopic eczema/dermatitis syndrome. Relation to clinical status. Allergy,2002, 57:732-736.
[18] Braccioni F, Dorman SC, O'byrne PM,et al. The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. J Allergy Clin Immunol,2002, 110:96-101.
[19] Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria:a single-blind, placebocontrolled, crossover clinical study. J Allergy Clin Immunol, 2002,110:484-488.
[20] Zhang J, Chervinsky P, Edwards T, et al. Montelukast, a Cys LT1receptor antagonist, decreases peripheral blood eosinophils and improves signs and symptoms of asthma over a 3 month period. J Allergy Clin Immunol, 1997, 99(Suppl):S52-S68.
[21] Capella GL, Grigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur J Dermatol, 2001, 11:209-213.
[22] Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol,2001, 44:89-93.
[23] Nettis E, Pannofino A, Fanelli M, et al. Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta Derm Venereol, 2002,82:297-298.
[24] Carucci JA, Washenik K, Weinstein A, et al. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol, 1998, 134:785-786.
[25] Chari S, Clark-Loeser L, Shupack J, et al. A role for leukotriene antagonists in atopic dermatitis? Am J Clin Dermatol, 2001,2:1-6.
[26] Woodmansee DP, Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol, 1999,83(6 Pt 1):548-552.
[27] Wenzel SE, Kamada AK. Zileuton:the first 5-1ipoxygenase inhibitorfor the treatmeent of asthma. Ann Pharmacother, 1996, 30:858-864.